Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

VKTX

Viking Therapeutics Inc

Jan 09 • 04:00PM ET

31.99

+0.34 1.07 %

Healthcare • Biotechnology • USA • NASD

Peers: MDGL AKRO GLMD AKBA ATON ARDX BOLD TVRD EYPT KYNB

| Held by: VTI VB XBI VBK VXF SCHA IWR VHT IWD IWS

Index	-	P/E	-	EPS (ttm)	-2.12	Insider Own	2.83%	Shs Outstand	112.45M	Perf Week	-9.68%
Market Cap	3.58B	Forward P/E	-	EPS next Y	-3.75	Insider Trans	-13.08%	Shs Float	109.70M	Perf Month	-14.19%
Enterprise Value	2.86B	PEG	-	EPS next Q	-0.90	Inst Own	65.24%	Short Float	21.90%	Perf Quarter	-8.55%
Income	-237.39M	P/S	-	EPS this Y	-169.43%	Inst Trans	-3.21%	Short Ratio	6.66	Perf Half Y	2.83%
Sales	0.00M	P/B	5.04	EPS next Y	-37.85%	ROA	-28.31%	Short Interest	24.03M	Perf YTD	-9.07%
Book/sh	6.34	P/C	5.01	EPS next 5Y	-	ROE	-29.23%	52W High	43.15 -25.86%	Perf Year	-23.21%
Cash/sh	6.39	P/FCF	-	EPS past 3/5Y	-12.29% -23.00%	ROIC	-33.28%	52W Low	18.92 69.08%	Perf 3Y	279.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.39% 4.38%	Perf 5Y	451.55%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-126.16%	Oper. Margin	-	ATR (14)	1.68	Perf 10Y	838.12%
Dividend Ex-Date	-	Quick Ratio	28.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.13	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	28.34	EPS Q/Q	-259.40%	SMA20	-8.44%	Beta	0.75	Target Price	93.39
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-11.44%	Rel Volume	0.79	Prev Close	31.65
Employees	36	LT Debt/Eq	0.00	Earnings	Oct 22 AMC	SMA200	4.76%	Avg Volume	3.61M	Price	31.99
IPO	Apr 29, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.15% -	Trades		Volume	2,867,555	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Initiated	Canaccord Genuity	Buy	$106
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$104
Apr-08-25	Initiated	Goldman	Neutral	$30
Feb-13-25	Initiated	Scotiabank	Sector Outperform	$102
Feb-07-25	Initiated	Citigroup	Neutral	$38
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy	$109
Nov-04-24	Reiterated	H.C. Wainwright	Buy	$90 → $102
Sep-11-24	Initiated	JP Morgan	Overweight	$80
Jun-27-24	Initiated	Morgan Stanley	Overweight	$105
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$115 → $116
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14

Show Previous Ratings

Jan-09-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know (Zacks)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
07:12AM	Viking Therapeutics completes enrollment in trial of VK2735 (TipRanks)
Jan-08-26 08:38PM	Lightning Round: QXO is a buy, says Jim Cramer (CNBC TV)
09:30AM	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
07:00AM	Loading…
07:00AM	Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PR Newswire)
Jan-07-26 07:00AM	Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer (PR Newswire)
Jan-06-26 09:41AM	Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026? (Zacks)
Jan-05-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -9.26%
04:03PM	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks)
08:34AM	Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026? (Zacks)
Jan-02-26 09:01AM	Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III (Zacks)
Dec-31-25 09:15AM	2 Beaten-Down Stocks That Could Bounce Back in 2026 (Motley Fool)
08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
05:45PM	Loading…
Dec-30-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Dec-29-25 02:34PM	This Small But Mighty Stock Could Surprise Investors in 2026 (Barchart)
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:01PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? (Zacks)
08:58AM	Premarket Movers: Albemarle Gaining Momentum on Lithium Boom (24/7 Wall St.)
Dec-22-25 06:46PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
06:50AM	Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) (Insider Monkey)
Dec-18-25 01:13PM	Viking Therapeutics, Inc. (VKTX): A Bull Case Theory (Insider Monkey)
12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
09:53AM	Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share? (Zacks)
Dec-16-25 01:35PM	1 Bold Prediction for Viking Therapeutics in 2026 (Motley Fool)
10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
11:11PM	Loading…
Dec-15-25 11:11PM	Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development (Insider Monkey)
05:45PM	Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-13-25 04:30AM	My Top 10 Stocks to Buy for 2026 (Motley Fool)
Dec-12-25 11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
07:44AM	This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street (Insider Monkey)
07:35AM	3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 (Motley Fool)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
07:10AM	Bullish Analysts Just Cant Quit Strategy Shares After 60% Rout (Bloomberg)
Dec-09-25 09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily) +8.92%
11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
Dec-03-25 09:26AM	Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? (Zacks)
Dec-02-25 12:28PM	LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website (Zacks)
Dec-01-25 09:26AM	VKTX Stock Rises 34% in Three Months: Here's What You Should Know (Zacks) -6.14%
Nov-29-25 01:08PM	Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating (Insider Monkey)
Nov-28-25 09:30AM	Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? (Zacks)
Nov-27-25 11:30AM	Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:24AM	Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy (Zacks)
08:15AM	Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 (Motley Fool)
Nov-26-25 10:45AM	NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes (Zacks)
Nov-25-25 04:05PM	Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-24-25 08:30AM	Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand? (Zacks)
08:19AM	Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps (Investor's Business Daily)
08:16AM	Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally (Zacks)
Nov-22-25 09:20AM	2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon (Motley Fool)
Nov-21-25 11:30AM	Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
04:31AM	3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential (Motley Fool)
Nov-20-25 11:30AM	VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug (Zacks)
Nov-19-25 04:22PM	Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win (Investor's Business Daily)
06:05AM	Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
02:55AM	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 (PR Newswire)
Nov-18-25 06:45AM	2 No-Brainer Healthcare Stocks to Buy Now (Motley Fool)
Nov-17-25 10:24AM	NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock? (Zacks)
Nov-14-25 08:53AM	Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance? (Zacks)
Nov-12-25 09:30AM	Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? (Zacks)
08:34AM	Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3? (Zacks)
Nov-11-25 10:08AM	Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.49%
Nov-10-25 08:19PM	William Blair Reiterates "Buy" Rating on Viking Therapeutics (VKTX) Following New VK2735 Data (Insider Monkey)
10:26AM	Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook? (Zacks)
04:45AM	2 Monster Stocks in the Making (Motley Fool)
Nov-09-25 06:55AM	Is There a Future for Viking Therapeutics? (Motley Fool)
Nov-07-25 10:44AM	LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs (Zacks)
08:02AM	The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. (Investor's Business Daily)
Nov-06-25 02:19PM	Jim Cramer Recommends Eli Lilly Over Viking Therapeutics (Insider Monkey)
07:05AM	Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek 2025 (PR Newswire)
Nov-05-25 05:15AM	Here's Why Shares in Viking Therapeutics Shot Higher in October (Motley Fool) +5.31%
Nov-04-25 11:17PM	Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer (CNBC TV)
08:10PM	Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. (Motley Fool)
04:05PM	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
01:35PM	Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera (Barrons.com)
Nov-03-25 11:41AM	Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock? (Zacks) -5.46%
11:13AM	Viking Therapeutics Could Be Pharmas Next Big Buyout Target (24/7 Wall St.)
04:45AM	Prediction: The Next Eli Lilly Might Already Be Trading Under $50 (Motley Fool)
Nov-02-25 09:20AM	Should You Buy Viking Therapeutics Before Nov. 5? (Motley Fool)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
04:55AM	3 Promising Growth Stocks That Are Down Around 60% From Their Highs (Motley Fool)
Oct-30-25 10:40AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.) +8.38%
Oct-29-25 04:05PM	Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 (PR Newswire)
09:35AM	Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 09:30AM	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:05AM	Viking Therapeutics: High Risk, High Reward Play (MarketBeat)
Oct-23-25 04:13PM	Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies (Investor's Business Daily) +7.96%
02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
02:36PM	Here's Why This Obesity Drug Company's Share Price Soared Today (Motley Fool)
10:39AM	Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05 08:31 PM
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,405	409,190	Jan 05 08:31 PM
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05 08:28 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05 08:25 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05 08:25 PM
MARIANNA MANCINI	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,406		Jan 05 04:32 PM
GREG ZANTE	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,470		Jan 05 04:30 PM
BRIAN LIAN	Officer	Jan 05 '26	Proposed Sale	32.96	233,409	7,692,134		Jan 05 04:29 PM
MATTHEW W. FOEHR	Director	Jan 02 '26	Proposed Sale	35.11	16,000	561,694		Jan 02 04:46 PM
Mancini Marianna	Chief Operating Officer	Oct 28 '25	Sale	35.00	6,185	216,492	382,467	Oct 28 07:51 PM
Rowland Charles A Jr	Director	Oct 27 '25	Sale	35.57	60,000	2,134,278	30,000	Oct 28 07:49 PM
Lian Brian	President & CEO	Oct 28 '25	Sale	35.01	38,989	1,364,923	2,419,109	Oct 28 07:48 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '25	Sale	35.00	6,185	216,481	173,592	Oct 28 07:47 PM
GREG ZANTE	Officer	Oct 28 '25	Proposed Sale	35.01	6,185	216,531		Oct 28 04:34 PM
MARIANNA MANCINI	Officer	Oct 28 '25	Proposed Sale	35.00	6,185	216,492		Oct 28 04:32 PM
BRIAN LIAN	Officer	Oct 28 '25	Proposed Sale	35.01	38,989	1,364,923		Oct 28 04:27 PM
CHARLES A ROWLAND JR.	Director	Oct 27 '25	Proposed Sale	35.57	60,000	2,134,278		Oct 27 04:25 PM
Lian Brian	President & CEO	Jul 03 '25	Sale	27.80	26,889	747,633	2,388,014	Jul 03 03:31 PM
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03 03:31 PM
Mancini Marianna	Chief Operating Officer	Jul 03 '25	Sale	27.77	4,266	118,473	377,535	Jul 03 03:30 PM
GREG ZANTE	Officer	Jul 03 '25	Proposed Sale	27.76	4,266	118,428		Jul 03 01:07 PM
MARIANNA MANCINI	Officer	Jul 03 '25	Proposed Sale	27.77	4,266	118,473		Jul 03 01:05 PM
BRIAN LIAN	Officer	Jul 03 '25	Proposed Sale	27.80	26,889	747,633		Jul 03 01:01 PM
FOEHR MATTHEW W	Director	Apr 11 '25	Option Exercise	8.00	20,786	166,288	132,036	Apr 14 07:26 PM
Rouan Sarah Kathryn	Director	Mar 31 '25	Buy	24.15	1,240	29,943	1,240	Apr 02 06:29 PM

Open in Screener

OABI

OmniAb Inc

Jan 09 • 04:00PM ET

1.91

+0.02 1.06 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: IWM VTI VXF IBB IWN SCHA VTWO IWC VHT DFAT

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.29%	Shs Outstand	143.96M	Perf Week	1.60%
Market Cap	272.08M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.09%	Shs Float	108.99M	Perf Month	-4.02%
Enterprise Value	233.65M	PEG	-	EPS next Q	-0.09	Inst Own	43.95%	Short Float	4.84%	Perf Quarter	4.95%
Income	-63.67M	P/S	12.90	EPS this Y	11.27%	Inst Trans	4.34%	Short Ratio	9.60	Perf Half Y	-5.91%
Sales	21.09M	P/B	0.99	EPS next Y	27.69%	ROA	-19.86%	Short Interest	5.27M	Perf YTD	3.24%
Book/sh	1.93	P/C	4.57	EPS next 5Y	20.72%	ROE	-22.37%	52W High	4.02 -52.49%	Perf Year	-47.53%
Cash/sh	0.42	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-21.61%	52W Low	1.22 56.56%	Perf 3Y	-40.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	8.77%	Volatility	3.91% 5.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	11.08	EPS Y/Y TTM	5.16%	Oper. Margin	-321.85%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.00	Sales Y/Y TTM	3.36%	Profit Margin	-301.83%	RSI (14)	51.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.00	EPS Q/Q	9.94%	SMA20	-2.82%	Beta	0.15	Target Price	7.33
Payout	-	Debt/Eq	0.08	Sales Q/Q	-46.33%	SMA50	6.79%	Rel Volume	0.44	Prev Close	1.89
Employees	114	LT Debt/Eq	0.06	Earnings	Nov 04 AMC	SMA200	8.25%	Avg Volume	549.02K	Price	1.91
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.67% -48.98%	Trades		Volume	239,490	Change	1.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
06:35PM	Loading…
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
06:15PM	Loading…
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
08:00AM	Loading…
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM

VKTX

Viking Therapeutics Inc

OABI

OmniAb Inc

Upgrade your FINVIZ experience